Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, D-66123 Saarbrücken, Germany.
Department of Chemistry, Virginia Tech, Blacksburg, VA 24061, United States; Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA 24061, United States.
Eur J Pharm Biopharm. 2019 Nov;144:110-124. doi: 10.1016/j.ejpb.2019.09.002. Epub 2019 Sep 4.
Inhalation therapy has been reported as the most effective treatment for respiratory bacterial infections due to the increasing relevance of drug bioavailability. Drug delivery systems (DDS) have the capacity to overcome pulmonary biological barriers limiting the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial infections and to prevent the development of bacterial resistance. Despite substantial efforts in the field, the current state-of-the-art often fails to achieve those goals, and we still observe increasing bacterial resistance. We give a brief insight on benefits and challenges in pulmonary delivery of anti-infectives. In the context of drug delivery development for pulmonary infections, particularly focusing on Pseudomonas aeruginosa (PA) infections, this mini review will critically discuss the main requirements, as well as the recent strategies of drug delivery system synthesis and preparation. Finally, interaction of DDS with crucial pulmonary biological barriers will be of great importance for the success of future applications of the developed DDS.
吸入疗法由于药物生物利用度的相关性不断增加，被报道为治疗呼吸道细菌感染最有效的方法。药物传递系统（DDS）有能力克服限制吸入性抗感染药物生物利用度的肺部生物学屏障。这对于消除细菌感染和防止细菌耐药性的发展非常重要。尽管在该领域进行了大量的努力，但目前的技术水平往往无法实现这些目标，而且我们仍在观察到细菌耐药性的不断增加。我们简要介绍了抗感染药物肺部传递的益处和挑战。在针对肺部感染的药物传递开发的背景下，特别是针对铜绿假单胞菌（PA）感染，本综述将批判性地讨论主要要求，以及药物传递系统合成和制备的最新策略。最后，DDS 与关键肺部生物屏障的相互作用对于未来开发的 DDS 的成功应用非常重要。
